220 related articles for article (PubMed ID: 15540564)
1. [Warning signals insulin resistance. Insulin resistance causes not only diabetes].
MMW Fortschr Med; 2004 Jul; 146(29-30):49. PubMed ID: 15540564
[No Abstract] [Full Text] [Related]
2. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
3. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
4. [Glitazones critically evaluated].
Schernthaner G
Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
[No Abstract] [Full Text] [Related]
5. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
[No Abstract] [Full Text] [Related]
6. [World news in age-related diabetes: blood sugar lowering can improve prognosis].
Einecke D
MMW Fortschr Med; 2005 Sep; 147(38):1. PubMed ID: 16218218
[No Abstract] [Full Text] [Related]
7. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
[No Abstract] [Full Text] [Related]
8. Insulin initiation in Type 2 diabetes.
Page S
Diabet Med; 2005 Sep; 22 Suppl 4():2-5. PubMed ID: 16109011
[No Abstract] [Full Text] [Related]
9. [Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].
MMW Fortschr Med; 2003 Sep; 145(38):61. PubMed ID: 14603688
[No Abstract] [Full Text] [Related]
10. Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
Shin JJ; Rothman J; Farag A; McFarlane SI; Sowers JR
Minerva Med; 2003 Dec; 94(6):401-8. PubMed ID: 14976468
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients.
Tseng CH; Huang TS
Diabetes Res Clin Pract; 2005 Nov; 70(2):193-4. PubMed ID: 16188579
[No Abstract] [Full Text] [Related]
12. The role of the thiazolidinediones in the practical management of patients with type 2 diabetes and cardiovascular risk factors.
Edelman SV
Rev Cardiovasc Med; 2003; 4 Suppl 6():S29-37. PubMed ID: 14668701
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
Hanefeld M
Int J Clin Pract Suppl; 2007 Jun; 61(153):20-7. PubMed ID: 17594390
[TBL] [Abstract][Full Text] [Related]
14. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
Inzucchi SE
Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
[No Abstract] [Full Text] [Related]
15. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
Fonseca VA
Am J Med; 2007 Sep; 120(9 Suppl 2):S18-25. PubMed ID: 17826042
[TBL] [Abstract][Full Text] [Related]
16. Potential cardiovascular benefits of insulin sensitizers.
Kunhiraman BP; Jawa A; Fonseca VA
Endocrinol Metab Clin North Am; 2005 Mar; 34(1):117-35. PubMed ID: 15752925
[TBL] [Abstract][Full Text] [Related]
17. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
18. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
[TBL] [Abstract][Full Text] [Related]
19. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
20. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]